However, first line and second line therapies in GVHD also harbor the risk of viral re-activation and overall significant improvement in efficacy outcomes by more target specific TF inhibitors probably weights more than a moderate elevated risk for infection (198, 235). The gene discussed is TF; the disease is graft versus host disease.